Pfizer Breast Cancer Drug Ibrance Demonstrates Impressive Results

April 15, 2015 7:55 PM

17 0

Pfizer announced that Ibrance, its treatment for advanced cancer demonstrated impressive results during the late-stage trial, which was stopped early because of its efficacy.

According to the company, the Phase 3 PALOMA-3 trial from Ibrance met its primary endpoint. The treatment demonstrated improvement in progression-free survival (PFS) for the combination of Ibrance plus fulvestrant in women with advanced breast cancer.

Also read: Medtronic settles states' probe into Infuse marketing for $12 million

Read more

To category page